HIV/AIDS Therapy

Lipid levels were not increased in patients with HIV taking MK-0518

Published in Health and Medicine Week, October 23rd, 2006

Levels of total cholesterol and triglycerides were not increased in HIV-infected patients taking MK-0518, an investigational integrase inhibitor being developed by Merck & Co., Inc., with tenofovir (Viread) and lamivudine (Epivir).

In contrast, increased levels of both lipid parameters were observed in patients taking efavirenz (Sustiva) combined with the same drugs.

The interim 24-week results are from an ongoing 48-week study in 198 treatment-naive HIV-infected patients, and were presented by Merck as a late breaker at the American Society for Microbiology's 46th annual International Conference on Antimicrobial Agents and Chemotherapy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2006-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry